Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma

Next Previous
Trial Profile

A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Amgen

Most Recent Events

  • 12 Jan 2026 Status changed from recruiting to active, no longer recruiting.
  • 30 Oct 2025 Planned End Date changed from 25 Jan 2027 to 25 Jan 2028.
  • 30 Oct 2025 Planned primary completion date changed from 25 Jan 2027 to 25 Jan 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top